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Abstract. Multimorbid patients are prescribed a number of medications in parallel, 
which may often interact with each other, resulting in adverse effects. However, 
clinical guidelines on prescription of medications predominantly focus on individual 
conditions do not consider the guidance in the context of other guidelines, resulting 
in conflicts. C3-Cloud is an integrated care architecture managing multimorbidity, 
which amongst others, provides clinical decision support, based on reconciled 
guidelines, and active monitoring of drug interactions. To identify the severe 
interactions that resulted from multimorbidity management, in order to reevaluate 
guidelines as well as to identify knowledge gaps in prescribing practice. Method: 
Descriptive statistical analysis of interactions identified by the C3-Cloud clinical 
decision support, collected from the C3-Cloud FHIR repository. As part of a 
feasibility study, a number of interactions were identified, along with variable 
practice in how chemicals are represented in the EHR. 191 known severe 
interactions were identified. The Atorvastatin/Verapamil interaction was the most 
frequent. The approach has identified a number of interactions where the severity 
was not available, highlighting the need for further clinical review.  
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1. Introduction 
Multi-morbidity creates diverse, and sometimes, contradictory needs, which challenge 
patients and the delivery of health services [1]. The clinical management of patients with 
multi-morbidity is much more complex and time-consuming than that of those with 
single diseases [2]. Uncoordinated multiple treatment regimens to address multi-
morbidity often result in unmanaged poly-pharmacy, which leads to increased potential 
for adverse drug interactions and poor adherence to treatment and medication [3]. This 
may result in Adverse Drug Events (ADE), which may be mistakenly seen as a separate 
diagnostic event and treated with more medications [4]. The paper is analyzing early 
results of a clinical decision support system, incorporating drug interaction advisories, 
used as part of an integrated care architecture for management of multimorbidity. 
 
1  Corresponding Author, George Despotou, Institute of Digital Healthcare, WMG, University of 
Warwick, CV4 7AL, Coventry UK, E-mail: g.despotou@warwick.ac.uk  
Public Health and Informatics
J. Mantas et al. (Eds.)
© 2021 European Federation for Medical Informatics (EFMI) and IOS Press.
This article is published online with Open Access by IOS Press and distributed under the terms
of the Creative Commons Attribution Non-Commercial License 4.0 (CC BY-NC 4.0).
doi:10.3233/SHTI210237
580
C3-Cloud is an e-health ICT system, offering integrated, patient-centered care, 
considering all aspects of multi-morbidity, creating a collaborative environment for all 
involved stakeholders [5]. C3-Cloud was deployed in 3 pilot sites in: Basque country, 
Spain; region Jämtland Härjedalen, Sweden; and Warwickshire, UK. The core of the 
system consists of the patient care plan, a digital shared picture of the patients’ needs and 
care goals. The care plan allows all professionals to review and understand the 
implications of one condition in the presence of others. This by its nature is a complex 
task, containing a considerable amount of diverse information. Drug safety in C3-Cloud 
is achieved by two means: a) offline (static) reconciliation of guidelines by clinicians, 
and b) dynamic drug interaction advisories provided by the C3-Cloud Drug Interaction 
Advisory Service (DIAS) [6], as part of its clinical decision support suite. Figure 1 shows 
an example of how the request to the DIAS service is made. A series of Anatomical 
Therapeutic Chemical (ATC) [7] codes to be checked (J01CA04, B01AA03, G03XA01) 
are sent to the service via an http request, and a list of interactions amongst them is 
returned in JSON. This occurs when physicians enter a new prescription to the system. 
If an interaction is detected, its effect is presented to physicians, who have the option to 
commit to, or amend the prescription.  
 
 
Figure 1. a) A typical DIAS GET request (top) b) extract from interactions returned in JSON (bottom). 
The C3-Cloud implementation, only returns interactions classified as severe. This 
was considered appropriate and manageable information load presented to physicians [8].  
Table 1. The guidelines used in C3-Cloud development and technology demonstrator. 
Condition NICE  Local Guideline 
Diabetes NG28 Osakidetza, Nationella riktlinjer för diabetesvård, Swedish Medical Products 
Agency drug treatment for type 2 Diabetes, American Diabetes Association and 
the European Association for the Study of Diabetes (ADA/EASD) on 
hyperglycemia, Joint British Diabetes Society (JBDS) guidelines, Scottish 




CG108 GuíaSalud, Nationella riktlinjer för hjärtsjukvård, European Society for 
Cardiology, British Society for Heart Failure, ‘Guidelines’. 
Chronic Kidney 
Disease 
CG182 Swedish association of nephrologists, International Kidney Disease/Improving 
Global Outcomes - KDIGO Guidelines, Renal Association guidelines. 
Depression CG90 GuíaSalud, Nationella riktlinjer för vård vid depression och ångestsyndrom. 
Hence, the ATC codes in the responses is a smaller subset of the codes in the request. 
Table 1 summarizes the guidelines used in C3-Cloud. Through a co-production process, 
the UK National Institute of Care Excellence (NICE) guidelines were adapted to 
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incorporate local practice, resulting in the C3-Cloud guidelines representing best 
common practice. The guidelines were analyzed for conflicts which were reconciled, and 
implemented as automated clinical decision support. Throughout the pilot, the users were 
informed by the clinical decision support system about the recommended way forward, 
based on the C3-Cloud guidelines. The final decision was made by the physician who 
may follow the recommendation, or use existing practice.  
2. Objectives and Method 
The objective is to analyze the interactions in order to understand: a) the most common 
drug risks associated with the C3-Cloud comorbidities, b) report to clinicians risks that 
were not addressed during offline reconciliation of guidelines, c) identify and report 
prescription habits of professionals that may not be covered by the guidelines, and d) 
identify knowledge gaps that will need to be bridged in order to inform practice.  
The responses of the drug interaction advisory service where analyzed, in order to 
identify the severe (i.e. life threatening or with permanent effects) interactions that were 
returned to system users. A total of 150 requests were analyzed that resulted in 357 
interactions. A further 166 interactions without available severity, were removed 
(although presented to users in C3-Cloud as they may result in severe effects), resulting 
in 191 known to be severe, interactions.  
3. Results  
Table 2 presents the 10 most common identified interactions, along with their potential 
effect and the evidence basis. All but three of the interactions are based on theoretical or 
anecdotal evidence.  
Table 2. The 10 most common interactions, the potential effect or increased risk of effect, and evidence basis 
for each interaction.  
 Interactants % Potential effect Evidence 
1 Atorvastatin/Verapamil 8.6 Increases exposure Study 
2 Bendroflumethiazide/Venlafaxine 4.6 Causes hypokalaemia Theoretical 
3 Clopidogrel/Pioglitazone 4.6 Increases exposure Study 
4 Bendroflumethiazide/Calcium 
gluconate 
2 Risk of hypercalcaemia Study 
5 Bendroflumethiazide/Fluconazole 2 Causes hypokalaemia Theoretical 
6 Bumetanide/Fluconazole 2 Causes hypokalaemia Theoretical 
7 Bumetanide/Venlafaxine 2 Causes hypokalaemia Theoretical 
8 Calcium 
gluconate/Chlorothiazide 
2 Risk of hypercalcaemia Anecdotal 
9 Calcium gluconate/Chlortalidone 2 Risk of hypercalcaemia Anecdotal 
10  Calcium gluconate/Clopamide 2 Risk of hypercalcaemia Anecdotal 
 
Table 3 shows the ATC codes of the drug that was being checked as part of a new 
prescription (based on all 357 interactions). It can be seen that the various medications 
were captured using various ATC levels, with the most common being drugs used in 
diabetes (A10 therapeutic subgroup), followed by ACE inhibitors (A09 therapeutic 
subgroup). Table 4 shows the ATC codes of the drugs that a potentially new prescription 
was checked against, showing the most common drugs already present in the patients’ 
Electronic Health Record (based on all 357 interactions). It is worth noticing that existing 
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drugs, were coded using multiple ATC groups, indicating the preference of the 
physicians to prescribe at the therapeutic group in some cases. 
Table 3. Percentage frequency of ATC codes that were requested to be checked for associations, and the ATC 
hierarchy level they correspond to. 
ATC Code % ATC Class ATC Level 
A10BG03 13.3% Pioglitazone 5 - chemical substance 
A10BH 13.3% Dipeptidyl peptidase 4 (DPP-4) inhibitors 4 - chemical subgroup 
C08 10% Calcium channel blockers 2 - therapeutic subgroup 
C09 6.7% ACE inhibitors 2 - therapeutic subgroup 
C10AA05 6% Atorvastatin 5 - chemical substance 
A10BA02 4% Metformin 5 - chemical substance 
C09A 4% ACE inhibitors 3 – pharmacological subgroup 
A10BB 3.3% Sulfonylureas 4 – chemical subgroup 
B01AC 2.7% Platelet aggregation inhibitors excl. heparin 4 – chemical subgroup 
C03 2.7% Diuretics 2 - therapeutic subgroup 
 
Table 4. Percentage frequency of ATC codes already present in the patients’ record at the time of the request. 
ATC Code % ATC Class ATC Level 
A10BA02 7.9% Metformin 5 - chemical substance 
B01AC06 7.3% Acetylsalicylic acid 5 - chemical substance 
C10AA05 5.4% Atorvastin 5 - chemical substance 
C08 5.1% Calcium channel blockers 2 - therapeutic subgroup 
C03 4.8% Diuretics 2 - therapeutic subgroup 
C09 4.7% ACE inhibitors 2 - therapeutic subgroup 
A10A 4.5% Insulins and analogues 3 – pharmacological subgroup 
D03 4.3% Dermatologicals 2 - therapeutic subgroup 
C07 3.9% Beta blocking agents 2 - therapeutic subgroup 
C07AB03 3.8% Atenolol 5 - chemical substance 
 
Table 5 presents the evidence basis of the 191 severe interactions. The majority of 
interactions relies on theoretical evidence (theoretical predictions, in vitro evidence, or 
by referencing other substances of the same group), whereas 21% relies on studies and a 
14% on anecdotal evidence (single or limited number of event reports).  
Table 5. Evidence basis of the identified interactions.  




4. Discussion and Conclusions 
The analysis based on this feasibility study identified 357 severe interactions. With the 
exception of the top 3 interactions, the rest were had a frequency of 2% or lower. 
However, even an interaction of lower frequency may affect a significant number of 
patients, when considering the entire population. Furthermore, it is worth considering 
that in the case of C3-Cloud, clinicians had already reconciled guidelines before the 
system’s implementation. This seeds some major questions about the extent of the 
problem, as most multimorbidity patients do not manage their conditions using 
reconciled guidelines, but the traditional segregated approach. The findings constitute 
early evidence of an issue that persists. Attempting to pre-reconcile all potential 
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interactions may not be practical, hence making clinical decision support in combination 
with access to the patient’s electronic health record, a valuable prescription tool.  
The approach has identified a number of interactions where the severity was not 
available. Although these were shown to the C3-Cloud physicians, they were not 
included in the results presented here, as we can’t know how many of them actually are 
severe. Further work will need to provide evidence for these interactions. Understanding 
the physicians’ decision making, in light of the interaction information remains to be 
studied. Additionally, only a 21% of interactions were based on evidence stemming from 
studies, with a 14% relying on anecdotal evidence. This further highlights the need to 
understand the confidence that we have in each type of evidence, as well as whether 
stronger evidence is necessary in order to inform clinical practice. Weaker evidence may 
be justifiably acceptable to inform guidelines [9]. The ATC codes show the trends on 
how new medication is represented in the system, and whether using (in some) high level 
ATC group (e.g., main anatomical group) is clinically equivalent to more detailed groups 
(e.g., chemical substance). It should be noted that the interactions represent practice from 
3 different sites in 3 different countries. Overall, the approach has managed to identify a 
number of potential issues to be further studied as part of the clinical practice of 
multimorbidity management.  
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